Rev-erbα agonist GSK4112 treatment in primary human lung fibroblasts and IPF lung tissue explant cultures have been shown to reduce TGFβ1-induced activation of ECM genes Acta2 and Col1a1 [9]. The gene discussed is ACTA2; the disease is idiopathic pulmonary fibrosis.